Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute

Bone Marrow Transplantation

Volumn 18, Issue 3, 1996, Pages 619-623

  Di Nicola, M ^a   Siena, S ^a,b   Bregni, M ^a   Belli, N ^a   Milanesi, M ^a   Ruffini, P A ^a   Malaffo, F ^a   Ravagnani, F ^a   Gianni, A M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Blood stem cell transplant; Cryopreservation; Oxypolygelatine

Indexed keywords

ANTINEOPLASTIC AGENT; CRYOPROTECTIVE AGENT; DIMETHYL SULFOXIDE; HETASTARCH; HUMAN SERUM ALBUMIN; OXYPOLYGELATIN; PLASMA PROTEIN; PLASMA SUBSTITUTE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION RISK; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; THAWING;

ADULT; CRYOPRESERVATION; GELATIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PLASMA SUBSTITUTES;

EID: 0029816195     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Juttner CA, Fibbe WE, Nemunaitis J et al. Blood cell transplantation: report from an International Consensus Meeting. Bone Marrow Transplant 1994; 14: 689-693.
2. Rowley SD. Hematopoietic stem cell cryopreservation: a review of current techniques. J Hematother 1992; 1: 233-250.
3. Groth J, Steinmann J, Eckstein V, Muller-Ruchholtz. Freezing of cells - replacement of serum by oxypolygelatine. J Immunol Meth 1991; 141: 105-109.
4. Gianni AM, Siena S, Bregni M et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more axillary nodes involved: 5-year results. J Clin Oncol (in press).
5. Ravagnani F, Siena S, Bregni M et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26: 562-564.
6. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
7. Siena S, Bregni M, Di Nicola M et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5: 935-941.
8. Stiff PJ, Koester AR, Weidner MK et al. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethyl-sulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987; 70: 974-978.
9. Makino S, Harada M, Akashi K et al. A simplified method for cryopreservation of peripheral blood stem cells at -80°C without rate-controlled freezing. Bone Marrow Transplant 1991; 8: 239-244.
10. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.
11. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
12. Rowley SD, Bensinger WI, Gooley TA, Buckner CD. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
13. Okamoto Y, Takaue Y, Saito S et al: Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer. Transfusion 1993; 33: 578-581.
14. Kessinger A, Schmit-Pokorny K, Smith D, Armitage JO. Preservation and infusion of autologous peripheral blood stem cells. Bone Marrow Transplant 1990; 5 (Suppl. 1): 25-27.
15. Gianni AM. Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 1994; 8: 781-784.